SA
BCLI

Sanctuary Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Sanctuary Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,147
Closed -$9.2K – 2449
2024
Q2 		$9.2K Buy
+1,147
New +$8.6K ﹤0.01% 2321

Other funds holding BCLI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Sanctuary Advisors's BCLI Position: Q3 2024 in Review

Sanctuary Advisors sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2024, closing a stake of 1,147 shares — an estimated $9.2K sold.

Sanctuary Advisors first reported a position in BCLI in Q2 2024 and held it in 1 quarter. The position peaked at $9.2K in Q2 2024. 38 funds tracked by Wall St. Rank hold BCLI as of Q3 2024.

  • Sanctuary Advisors reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2024 after selling out during the quarter.
  • Sanctuary Advisors sold 1,147 BRAINSTORM CELL THERAPUTC shares in Q3 2024, an estimated $9.2K.
  • Sanctuary Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2024 and held it in 1 quarter.
  • Sanctuary Advisors's BRAINSTORM CELL THERAPUTC position peaked at $9.2K in Q2 2024.
  • 38 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2024.

Based on Sanctuary Advisors's 13F filing for Q3 2024, filed 25 Nov 2024.